Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

 
• By Derrick Gingery
A crossover design could allow for more long-term safety and efficacy follow-up.

More from US FDA Performance Tracker

More from Regulatory Trackers